Self-Reported Adherence after Overnight Switching from Immediate- to Extended-Release Pramipexole in Parkinson’s Disease
Affiliation(s)
Department of Neurology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan.
Department of Neurology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan.
ABSTRACT
Background: Drug adherence decreased in patients with Parkinson’ s disease (PD) because of taking many different types of drugs. We evaluated drug adherence after switching from immediate-release (IR) to once-daily extended-release (ER) pramipexole (PPX) in PD. Methods: This study included 35 PD patients (20 men, 15 women); 10 were taking oral PPX alone, and 25 were also using another anti-PD drug. PPX-IR was switched overnight to PPX-ER without gradual tapering. One month after switching, improvement in timing adherence and reduction in medication burden were evaluated by a questionnaire using a visual analog scale (VAS) (0: No change; 10: Better). Motor function was assessed using part III of the Unified Parkinson’s Disease Rating Scale (UPDRS). Results: The VAS score for improvement in timing adherence was 8.1 ± 0.5 (mean ± standard error), and that for reduction in medication burden was 7.3 ± 0.6. There was a significant negative correlation (ρ = -0.43, p = 0.01) between the VAS score and number of types of medications. The UPDRS part III score improved significantly after switching (p < 0.01). Only one patient discontinued PPX-ER after switching. Conclusion: Switching from PPX-IR to once-daily PPX-ER is safe and improves motor function in patients by improving timing adherence and reducing medication burden.
KEYWORDS
Parkinson’s Disease, Timing Adherence, Pramipexole, Extended-Release, Immediate-Release, Motor Function
Parkinson’s Disease, Timing Adherence, Pramipexole, Extended-Release, Immediate-Release, Motor Function
Cite this paper
Iijima, M. , Osawa, M. , Maruyama, K. , Uchiyama, S. and Kitagawa, K. (2015) Self-Reported Adherence after Overnight Switching from Immediate- to Extended-Release Pramipexole in Parkinson’s Disease. Advances in Parkinson's Disease, 4, 13-19. doi: 10.4236/apd.2015.41003.
Iijima, M. , Osawa, M. , Maruyama, K. , Uchiyama, S. and Kitagawa, K. (2015) Self-Reported Adherence after Overnight Switching from Immediate- to Extended-Release Pramipexole in Parkinson’s Disease. Advances in Parkinson's Disease, 4, 13-19. doi: 10.4236/apd.2015.41003.
References
[1] Leopold, N.A., Polansky, M. and Hurka, M.R. (2004) Drug Adherence in Parkinson’s Disease. Movement Disorders, 19, 513-517. http://dx.doi.org/10.1002/mds.20041 [2] Grosset, D.G., Antonini, A., Canesi, M., Pezzoli, G., Lees, A., Shaw, K., Esther Cubo, E., Martinez-Martin, P., Rascol, O., Negre-Pages, L., Senard, A., Schwarz, J., Strecker, K., Reichmann, H., Storch, A., L?hle, M., Stocchi, F. and Grosset, K. (2009) Adherence to Antiparkinson Medication in a Multicenter European Study. Movement Disorders, 24, 826-832. http://dx.doi.org/10.1002/mds.22112 [3] Kulkarni, A.S., Balkrishnan, R., Anderson, R.T., Edin, H.M., Kirsch, J. and Stacy, M.A. (2009) Medication Adherence and Associated Outcomes in Medicare Health Maintenance Organization-Enrolled Older Adults with Parkinson’s Disease. Movement Disorders, 23, 359-365. http://dx.doi.org/10.1002/mds.21831 [4] Valldeoriola, F., Coronell, C., Pont, C., Cámara, C., Gaig , C. and Compta, Y., on Behalf of the Members of the ADHESON Study Group (2011) Socio-Demographic and Clinical Factors Influencing the Adherence to Treatment in Parkinson’s Disease: The ADHESON Study. European Journal of Neurology, 13, 980-987. http://dx.doi.org/10.1111/j.1468-1331.2010.03320.x [5] Daley, D.J., Myint, P.K., Gray, R.J. and Deane, K.H. (2012) Systematic Review on Factors Associated with Medication Non-Adherence in Parkinson’s Disease. Parkinsonism & Related Disorders 18, 1053-1061. http://dx.doi.org/10.1016/j.parkreldis.2012.09.004 [6] Schapira, A.H.V., Barone, P., Hauser, R.A., et al. (2013) Patient-Reported Convenience of Once-Daily versus Three- Times-Daily Dosing during Long-Term Studies of Pramipexole in Early and Advanced Parkinson’ s Disease. European Journal of Neurology, 20, 50-56. http://dx.doi.org/10.1111/j.1468-1331.2012.03712.x [7] Takanashi, M., Shimo, Y., Hatano, T., Oyama, G. and Hattori, N. (2013) Efficacy and Safety of a Once-Daily Extended-Release Formulation of Pramipexole Switched from an Immediate-Release Formulation in Patients with Advanced Parkinson’s Disease: Results from an Open-Label Study. Drug Research, 63, 639-643. http://dx.doi.org/10.1055/s-0033-1351257 [8] Grosset, K.A. and Grosset, D.G. (2007) Effect of Educational Intervention on Medication Timing in Parkinson’s Disease: A Randomized Controlled Trial. BMC Neurology, 7, 20. http://dx.doi.org/10.1186/1471-2377-7-20 [9] Santos-García, D., Prieto-Formoso, M. and Fuente-Fernández, R. (2012) Levodopa Dosage Determines Adherence to Long-Acting Dopamine Agonists in Parkinson’s Disease. Journal of the Neurological Sciences, 318, 90-93. http://dx.doi.org/10.1016/j.jns.2012.03.018 [10] Grosset, K.A., Bone, I., Reid, J.L. and Grosset, D.G. (2006) Measuring Therapy Adherence in Parkinson’s Disease: A Comparison of Methods. Journal of Neurology, Neurosurgery & Psychiatry, 77, 249-251. http://dx.doi.org/10.1136/jnnp.2005.064709 [11] Elm, J.J., Kamp, C., Tilley, B.C., Guimaraes, P., Fraser, D., Deppen, P., Brocht, A., Weaver, C., Bennett, S., for NINDS NET-PD Investigators and Coordinators (2007) Self-Reported Adherence versus Pill Count in Parkinson’s Disease: The NET-PD Experience. Movement Disorders, 22, 822-827. http://dx.doi.org/10.1002/mds.21409 [12] Tarrants, M.L., Denarié, M.F., Castelli-Haley, J., Millard, J. and Zhang, D. (2010) Drug Therapies for Parkinson’s Disease: A Database Analysis of Patient Compliance and Persistence. The American Journal of Geriatric Pharmacotherapy, 8, 374-383. http://dx.doi.org/10.1016/j.amjopharm.2010.08.001 [13] Rascol, O., Barone, P., Hauser, R.A., Mizuno, Y., Poewe, W., Schapira, A.H.V., Salin, L., Sohr, M. and Debieuvre, C. (2010) Efficacy, Safety, and Tolerability of Overnight Switching from Immediate- to Once Daily Extended-Release Pramipexole in Early Parkinson’s Disease. Movement Disorders, 25, 2326-2332. http://dx.doi.org/10.1002/mds.23262 [14] Mizuo, Y., Yamamoto, M., Kuno, S., Hasegawa, K., Hattori, N., Kagimura, T., Sarashina, A., Rascol, O., Schapira, A.H.V., Barone, P., Hauser, R., Poewe, W., The Pramipexole ER Study Group (2012) Efficacy and Safety of Extended- versus Immediate- Release Pramipexole in Japanese Patients with Advanced and L-dopa-Undertreated Parkinson Disease: A Double-Blind, Randomized Trial. Clinical Neuropharmacology, 35, 174-181. http://dx.doi.org/10.1097/WNF.0b013e31825f77b9 [15] Schapira, A.H., Barone, P., Hauser, R.A., Mizuno, Y., Rascol, O., Busse, M., Debieuvre, C., Fraessdorf, N. and Poewe, W. (2013) Success Rate, Efficacy, and Safety/Tolerability of Overnight Switching from Immediate- to Extended-Re- lease Pramipexole in Advanced Parkinson’s Disease. European Journal of Neurology, 20, 180-187. http://dx.doi.org/10.1111/j.1468-1331.2012.03822.x [16] Bainbridge, J.L. and Ruscin, J. (2009) Challenges of Treatment Adherence in Older Patients with Parkinson’s Disease. Drugs & Aging, 26,145-155. http://dx.doi.org/10.2165/0002512-200926020-00006
[1] Leopold, N.A., Polansky, M. and Hurka, M.R. (2004) Drug Adherence in Parkinson’s Disease. Movement Disorders, 19, 513-517. http://dx.doi.org/10.1002/mds.20041 [2] Grosset, D.G., Antonini, A., Canesi, M., Pezzoli, G., Lees, A., Shaw, K., Esther Cubo, E., Martinez-Martin, P., Rascol, O., Negre-Pages, L., Senard, A., Schwarz, J., Strecker, K., Reichmann, H., Storch, A., L?hle, M., Stocchi, F. and Grosset, K. (2009) Adherence to Antiparkinson Medication in a Multicenter European Study. Movement Disorders, 24, 826-832. http://dx.doi.org/10.1002/mds.22112 [3] Kulkarni, A.S., Balkrishnan, R., Anderson, R.T., Edin, H.M., Kirsch, J. and Stacy, M.A. (2009) Medication Adherence and Associated Outcomes in Medicare Health Maintenance Organization-Enrolled Older Adults with Parkinson’s Disease. Movement Disorders, 23, 359-365. http://dx.doi.org/10.1002/mds.21831 [4] Valldeoriola, F., Coronell, C., Pont, C., Cámara, C., Gaig , C. and Compta, Y., on Behalf of the Members of the ADHESON Study Group (2011) Socio-Demographic and Clinical Factors Influencing the Adherence to Treatment in Parkinson’s Disease: The ADHESON Study. European Journal of Neurology, 13, 980-987. http://dx.doi.org/10.1111/j.1468-1331.2010.03320.x [5] Daley, D.J., Myint, P.K., Gray, R.J. and Deane, K.H. (2012) Systematic Review on Factors Associated with Medication Non-Adherence in Parkinson’s Disease. Parkinsonism & Related Disorders 18, 1053-1061. http://dx.doi.org/10.1016/j.parkreldis.2012.09.004 [6] Schapira, A.H.V., Barone, P., Hauser, R.A., et al. (2013) Patient-Reported Convenience of Once-Daily versus Three- Times-Daily Dosing during Long-Term Studies of Pramipexole in Early and Advanced Parkinson’ s Disease. European Journal of Neurology, 20, 50-56. http://dx.doi.org/10.1111/j.1468-1331.2012.03712.x [7] Takanashi, M., Shimo, Y., Hatano, T., Oyama, G. and Hattori, N. (2013) Efficacy and Safety of a Once-Daily Extended-Release Formulation of Pramipexole Switched from an Immediate-Release Formulation in Patients with Advanced Parkinson’s Disease: Results from an Open-Label Study. Drug Research, 63, 639-643. http://dx.doi.org/10.1055/s-0033-1351257 [8] Grosset, K.A. and Grosset, D.G. (2007) Effect of Educational Intervention on Medication Timing in Parkinson’s Disease: A Randomized Controlled Trial. BMC Neurology, 7, 20. http://dx.doi.org/10.1186/1471-2377-7-20 [9] Santos-García, D., Prieto-Formoso, M. and Fuente-Fernández, R. (2012) Levodopa Dosage Determines Adherence to Long-Acting Dopamine Agonists in Parkinson’s Disease. Journal of the Neurological Sciences, 318, 90-93. http://dx.doi.org/10.1016/j.jns.2012.03.018 [10] Grosset, K.A., Bone, I., Reid, J.L. and Grosset, D.G. (2006) Measuring Therapy Adherence in Parkinson’s Disease: A Comparison of Methods. Journal of Neurology, Neurosurgery & Psychiatry, 77, 249-251. http://dx.doi.org/10.1136/jnnp.2005.064709 [11] Elm, J.J., Kamp, C., Tilley, B.C., Guimaraes, P., Fraser, D., Deppen, P., Brocht, A., Weaver, C., Bennett, S., for NINDS NET-PD Investigators and Coordinators (2007) Self-Reported Adherence versus Pill Count in Parkinson’s Disease: The NET-PD Experience. Movement Disorders, 22, 822-827. http://dx.doi.org/10.1002/mds.21409 [12] Tarrants, M.L., Denarié, M.F., Castelli-Haley, J., Millard, J. and Zhang, D. (2010) Drug Therapies for Parkinson’s Disease: A Database Analysis of Patient Compliance and Persistence. The American Journal of Geriatric Pharmacotherapy, 8, 374-383. http://dx.doi.org/10.1016/j.amjopharm.2010.08.001 [13] Rascol, O., Barone, P., Hauser, R.A., Mizuno, Y., Poewe, W., Schapira, A.H.V., Salin, L., Sohr, M. and Debieuvre, C. (2010) Efficacy, Safety, and Tolerability of Overnight Switching from Immediate- to Once Daily Extended-Release Pramipexole in Early Parkinson’s Disease. Movement Disorders, 25, 2326-2332. http://dx.doi.org/10.1002/mds.23262 [14] Mizuo, Y., Yamamoto, M., Kuno, S., Hasegawa, K., Hattori, N., Kagimura, T., Sarashina, A., Rascol, O., Schapira, A.H.V., Barone, P., Hauser, R., Poewe, W., The Pramipexole ER Study Group (2012) Efficacy and Safety of Extended- versus Immediate- Release Pramipexole in Japanese Patients with Advanced and L-dopa-Undertreated Parkinson Disease: A Double-Blind, Randomized Trial. Clinical Neuropharmacology, 35, 174-181. http://dx.doi.org/10.1097/WNF.0b013e31825f77b9 [15] Schapira, A.H., Barone, P., Hauser, R.A., Mizuno, Y., Rascol, O., Busse, M., Debieuvre, C., Fraessdorf, N. and Poewe, W. (2013) Success Rate, Efficacy, and Safety/Tolerability of Overnight Switching from Immediate- to Extended-Re- lease Pramipexole in Advanced Parkinson’s Disease. European Journal of Neurology, 20, 180-187. http://dx.doi.org/10.1111/j.1468-1331.2012.03822.x [16] Bainbridge, J.L. and Ruscin, J. (2009) Challenges of Treatment Adherence in Older Patients with Parkinson’s Disease. Drugs & Aging, 26,145-155. http://dx.doi.org/10.2165/0002512-200926020-00006